Eton Pharmaceuticals vs ARS Pharmaceuticals
ETON and SPRY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ETON and SPRY compare
Eton Pharmaceuticals is the larger company, worth 4.7 times as much as ARS Pharmaceuticals ($1.8B against $387M).
Eton Pharmaceuticals grew revenue faster over the last twelve months (101% versus −14.5% for ARS Pharmaceuticals).
Eton Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 35.3% compared with −164% at ARS Pharmaceuticals.
Eton Pharmaceuticals scores higher on the StockData Score (12 against 9 for ARS Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ETON | SPRY |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $387M |
| Share price | $63.93 | $3.89 |
| Change, 1 year | 266% | −56.5% |
| Change, 5 years | 1302% | −52.7% |
| Beta (5Y) | 0.88 | 1.42 |
| Employees | 44 | 158 |
| StockData Score | ||
| Total score | 12 (better) | 9 |
| Valuation score | 0 | 1 (better) |
| Growth score | 4 (better) | 2 |
| Performance score | 4 (better) | 1 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 42.1× | – |
| P/S | 13.0× | 3.2× (better) |
| P/B | 21.0× | – |
| EV/EBITDA | 39.3× | – |
| P/FCF | 47.8× | – |
| FCF yield | 2.1% (better) | −47.3% |
| Fair value | $33.76 | – |
| Margin of safety | −89.4% | – |
| Growth | ||
| Revenue growth (TTM) | 101% (better) | −14.5% |
| Revenue growth, 5Y average | 360% | – |
| Profitability | ||
| Gross margin | 69.2% | – |
| Operating margin | 28.8% (better) | −161% |
| Net margin | 35.3% (better) | −164% |
| FCF margin | 27.1% (better) | −150% |
| Return on equity | 90.6% (better) | −295% |
| Return on invested capital | 115% | – |
| Financial health | ||
| Debt / equity | 0.27 | – |
| Net debt / EBITDA | −0.71 | – |
| Current ratio | 1.79 | 3.25 (better) |
| Altman Z-score | 17.09 (better) | −3.05 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 74.0% | 91.2% |
| Held by insiders | 5.6% | 46.7% |
| Insider net buying, 12 months | −$35.0M | −$284K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 7.4% | 35.9% |
Go deeper
- ETON stock overview
- ETON income statement
- ETON valuation and score
- SPRY stock overview
- SPRY income statement
- SPRY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.